NEVVI Medicare utilization intelligence
+ Build a code basket
Market snapshot

Nationwide CY2024

Medicare Part B FFS · CY2024 · as published by CMS
Q2050 Injection, doxorubicin hydrochloride, liposomal, not otherwise specified, 10 mg HCPCS · Chemotherapy treatment
Classification Treatment › Chemotherapy › Chemotherapeutic Agent (CMS RBCS)
First observed 2013 — start of our 12-year window; the code predates it
National scale 1,699 services · est. · 36 FFS beneficiaries (CY2024, all-Medicare estimate) — 888 observed fee-for-service services
Medicare paid $155K · est. · $90.55 avg / service, national — $80K observed FFS
CMS descriptor · RBCS classification · Medicare Part B physician/supplier claims, 12-year window
Billing groups

3

Named groups billing this code
Named-group all-Medicare svcs · est.

1,699

Scaled from 888 observed FFS services.
FFS of Medicare

49%

Payer-mix frame
Services · year over year
Services YoY

-12.8%

All-Medicare est. · observed FFS -11.8%
Volume, not care. A shrinking fee-for-service denominator is not a shrinking market.
Estimated all-Medicare volume estimate
FFS + estimated MA

~1,699 services

888 observed fee-for-service (52%) · ~811 estimated Medicare Advantage.

Scaled from the observed floor by each state’s fee-for-service share (FFS share as of 2024) — scaled estimate — assumes MA utilization mirrors FFS; not an observation. How we scale
Top states — Q2050 (CY2024)
SC 715 FL 618 VA 365

Est. all-Medicare services by billing state (scaled estimate — assumes MA utilization mirrors FFS); open a bar for that state's ranked market.

Billed → allowed → paid
Named-group submitted charges
$1.0M
Named-group allowed amount
$101K
Named-group Medicare payments
$155K · est.
— $80K observed FFS
Avg charge / svc
$1,153
Avg allowed / svc
$114
Avg payment / svc
$91
Totals are named-group (attributable) sums. Allowed is Medicare’s fee-schedule recognized price — what CMS recognizes, before the 80% Medicare pays.
Average charge per group
$790 3 groups · avg submitted charge / service $2,157
Market analyticsPlatform Methods →

Search a single state to see that market's full analytics — each panel renders gated on the free tier.

See it in full: nuclear heart imaging (78452) in Arizona is open as a live example — every paid panel, on real data.

View the live example →
See the Platform — the full read, every number below, code baskets, and export. Notify me at launch →
Refine: group size any 5+ 25+ 100+ independent only
Filter results:

Email me this CSV

Data year: CY2024 CY2023 CY2022  CY2021  CY2020 
# Physician group City St Specialty Providers Q2050 svcs Submitted charges Avg charge Medicare $ Share of state* Phone
1 SOUTH CAROLINA ONCOLOGY ASSOC PA COLUMBIA SC HEMATOLOGY/ONCOLOGY 18 391 $322,575 $825 100.0% (803) 461-3000
2 FLORIDA CANCER SPECIALISTS AND RESEARCH INSTITUTE, LLC FORT MYERS FL HEMATOLOGY/ONCOLOGY 437 271 $214,090 $790 100.0% (239) 561-9622
3 VIRGINIA ONCOLOGY ASSOCIATES NORFOLK VA PHYSICIAN ASSISTANT 123 226 $487,396 $2,157 100.0% —

*Share of the state's disclosed Medicare-FFS services for the primary code, counted once per clinician. "St" is the state the volume was billed from: a group appears in each state where its clinicians bill Medicare, with that state's volume and share ("City" is the group's registered location). Group figures sum clinicians affiliated with exactly one group; clinicians in several groups are listed in each group's drill-down but not volume-attributed to any single group, so shares reflect attributable volume. See Methods.

Comparing against an all-payer estimate?

These are exact counts from Medicare fee-for-service claims — roughly a third to half of most procedure markets, depending on payer mix — and the observed foundation every market figure here builds on. Market totals anchor on a labeled all-Medicare estimate scaled from that foundation, with the observed count disclosed beside it — Medicare only, never all-payer. Modeled all-payer databases project every payer statistically and typically run higher. Same market, different denominator. How the numbers reconcile →